Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWZJT0)

Drug Name

PMID25489658C4d Drug Info

Synonyms

GTPL8483

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Kallikrein-5 (KLK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID23849879C3	DMUW3MT	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Suppressor of tumorigenicity 14 protein (ST14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8569313, Inhibitor 18	DMXTCGM	N. A.	N. A.	Patented	[4]
US8569313, Inhibitor 14	DMZV6YT	N. A.	N. A.	Patented	[4]
US8569313, Inhibitor 19	DMLXG43	N. A.	N. A.	Patented	[4]
US8569313, Inhibitor 15	DMTMG02	N. A.	N. A.	Patented	[4]
PMID23849879C3	DMUW3MT	Discovery agent	N.A.	Investigative	[3]
Benzamidine	DM37GWL	Discovery agent	N.A.	Investigative	[5]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	DMFXKN1	Discovery agent	N.A.	Investigative	[6]
Inhibitor 1 [Colombo et al., 2012]	DMUQHMP	Discovery agent	N.A.	Investigative	[7]
3-tapap	DMKSUV9	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Targeting Kallikrein-14 (KLK14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID23849879C3	DMUW3MT	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Kallikrein-7 (KLK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID23849879C3	DMUW3MT	Discovery agent	N.A.	Investigative	[3]
Antileukoprotease (ALP)	DMVF2YH	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kallikrein-14 (KLK14)	TTDA81R	KLK14_HUMAN	Inhibitor	[2]
Kallikrein-5 (KLK5)	TTULSEW	KLK5_HUMAN	Inhibitor	[2]
Kallikrein-7 (KLK7)	TTE6GTB	KLK7_HUMAN	Inhibitor	[2]
Suppressor of tumorigenicity 14 protein (ST14)	TTPRO7W	ST14_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000 Jun;25(2):141-2.
2	Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
3	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
4	Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
5	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418).
8	Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61.